اموكسكلاڤ تيڤع ٨٧٥ ملغ إسرائيل - العربية - Ministry of Health

اموكسكلاڤ تيڤع ٨٧٥ ملغ

salomon,levin & elstein ltd - amoxicillin as trihydrate 875 mg; clavulanic acid as potassium salt 125 mg - film coated tablets - ampicillin, combinations - short-term treatment of bacterial infections at the following sites: upper/lower respiratory tract infections, genito-urinary tract infections, skin and soft tissue infections, bone and joint infections, dental infections and other infections.

اوفلوكساسين تيڤع ٢٠٠ ملغ إسرائيل - العربية - Ministry of Health

اوفلوكساسين تيڤع ٢٠٠ ملغ

abic ltd. - ofloxacin 200 mg - tablets - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).

بيكالوتاميد تيڤع ٥٠ ملغ إسرائيل - العربية - Ministry of Health

بيكالوتاميد تيڤع ٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

ريزدرونات تيڤع ٣٥ ملغ إسرائيل - العربية - Ministry of Health

ريزدرونات تيڤع ٣٥ ملغ

abic marketing ltd - risedronic acid as sodium 35 mg - tablets - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.